MHRA approves Kostaive sa‑mRNA COVID booster for 18+
On 2 January 2026, the UK medicines regulator approved zapomeran (brand name Kostaive) for use in adults aged 18 and over. It’s a single 0.5 mL booster injected into the upper arm, using self‑amplifying mRNA to train your immune system. As the MHRA puts it, “Patient safety is our top priority.”
So, what is self‑amplifying mRNA? Think of regular mRNA vaccines as a one‑off set of instructions. With sa‑mRNA, those instructions also code for a helper enzyme (replicase) that briefly makes extra copies of the message inside your cells. That means more spike protein is shown to your immune system, using a small amount of vaccine, all wrapped in lipid nanoparticles to get the message into cells.
Let’s separate approval from rollout. Authorisation by the MHRA means the vaccine can be used, but it’s the NHS-following advice from the Joint Committee on Vaccination and Immunisation (JCVI)-that decides who is offered a dose. For autumn 2025, the programme focused on those at highest risk: adults 75+, residents in older adult care homes, and people who are immunosuppressed. JCVI also advises spacing doses by around six months where possible, with a three‑month minimum if needed; similar principles inform spring 2026 planning.
How Kostaive is used in practice: the EMA’s summary says adults receive one injection into the upper arm. If you’ve already had COVID‑19 vaccines, Kostaive should be given at least five months after your most recent dose, and people with severely weakened immunity may be offered additional doses based on national guidance.
What you might feel afterwards is familiar: a sore or tender arm, tiredness, chills, fever, muscle or joint aches, headache and dizziness. These very common effects usually settle within a few days. If symptoms worry you or persist, speak to a healthcare professional.
Safety monitoring doesn’t stop at approval. Anyone can report a suspected side effect through the MHRA’s Yellow Card website or app; this real‑world reporting helps regulators spot patterns quickly. If you’re concerned about your health, talk to a pharmacist or GP, or call NHS 111, then consider submitting a Yellow Card.
What this means if you’re 18–74 and otherwise well: authorisation doesn’t automatically mean you’ll be invited for a booster right now. The national programme targets people most likely to benefit, so check NHS updates if you’re in a clinical risk group or are immunosuppressed.
A quick science note for class or conversation: sa‑mRNA technology has been studied for over two decades. Kostaive is the first self‑amplifying mRNA COVID‑19 vaccine authorised in the EU, and, like other mRNA vaccines, the mRNA, replicase enzyme and spike protein are broken down after doing their job.
How the UK signed this off matters for media literacy. The MHRA used its International Recognition Procedure (IRP), which draws on work by trusted regulators-here the EMA-while keeping UK decision‑making independent. IRP routes typically run to 60–110 days, helping safe medicines reach patients sooner.
Practical next steps: the Patient Information Leaflet and Summary of Product Characteristics will be published by the MHRA within seven days of approval; these documents explain dosing, ingredients and rare risks in plain English. For personal advice on whether and when to get a booster, speak to your clinician and keep an eye on NHS announcements.